Skip to main content

Transgenomic, ScreenCell Partner on Distribution of Combined Technologies

NEW YORK (GenomeWeb News) – Transgenomic and ScreenCell today announced they have signed a perpetual, worldwide collaboration and distribution deal for ScreenCell's Isolation Devices and Diffusion Buffers in combination with Transgenomic's products.

Transgenomic will exclusively distribute ScreenCell's technologies designed for collecting circulating tumor cells for use in combination with its mutation detection products, such as its Ice-Cold PCR assays, Blocker-Sequencing cancer mutation assays, Surveyor Scan cancer mutation kits, and Wave instrument systems.

Transgenomic plans to sell the ScreenCell products immediately in combination with its own technology.

The firms also will support development of the combined technologies, which have been tested in a proof-of-concept study at the Dana Farber Cancer Institute. They plan additional validation work with the institute as well as other researcher institutions "to further establish the ability to isolate CTCs and, using the combined products, find new marker genes" for early diagnostics, and find mutations that may help with prognosis and therapeutic response.

Transgenomic plans to start validating the combined products immediately with the goal of commercializing them for clinical trial use.

The ScreenCell technology is designed for collecting circulating tumor cells in peripheral blood and offers single-use devices to isolate and characterize by size all possible tumor cells, including mesenchymal cells, which are not collected by technologies that target only cells expressing a transmembrane glycoprotein on epithelial cells called EpCam.

Craig Tuttle, president and CEO of Transgenomic, said that in combination with his firm's products, "we believe [the ScreenCell] platform may have a dramatic impact on disease detection, treatment, management, and outcome in cancer."

Transgenomic announced yesterday that Italy's A. Menarini Diagnostics will exclusively distribute its Surveyor Scan and Wave Micro-capillary electrophoresis mutation detection system throughout Europe.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.